NRx Pharmaceuticals, Inc. (NRXP), Thursday said it has submitted Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for preservative-free IV ketamine formulation, NRX-100, for all approved uses such as anesthesia and pain management.
NRx expects priority review from the FDA considering the current and anticipated drug shortage.
This filing supplements the New Drug Application for NRX-100 in suicidal depression with a PDUFA action date anticipated in late 2025.
The current annual ketamine market is estimated at $750 million with worldwide demand expected to increase to $3.35 billion by 2034.
The company anticipates filing a citizen's petition with the FDA to remove benzethonium chloride, a known neurotoxic and cytotoxic substance, from presentations of ketamine intended for intravenous use.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.